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Abstract
The advent of salicylates in the treatment of ulcerative colitis started in 1938 with the discovery
of Salazopyrin by Nanna Svartz. This drug offered for the first time a therapeutic chance to
patients with ulcerative colitis. In this paper we describe the fascinating history of Salazopyrin
and salicylates from the first serendipitous observations to the last randomized clinical trials.
Attention was paid to the pharmacokinetics and the mechanism of action of 5-aminosalicylates
and, in particular, to the issue of the mucosal concentrations of 5-aminosalicylates and its
therapeutic efficacy. Moreover a look at the new oral mesalazine formulations that allow the
homogenous distribution of 5-aminosalicylate through all the large bowel was taken. Lastly, the
possible use of mesalazine in the prevention of colorectal cancer was reviewed.
© 2009 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.a, 11, 00199 Rome, Italy. Tel.:
t (R. Caprilli).
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century was empirical, anecdotical and inefficacious. It
consisted of bed rest, low residue and high protein diet,
vitamin supplement, blood transfusion, opioids and rectal
instillation of various substances (hydrogen peroxide, silver
nitrate, tannic acid, and bismuth). The prognosis of patients
with UC at that time was poor and mortality was very high.
The discovery of Salazopyrin in 1938 significantly changed
the fate of these patients offering them, for the first time, a
therapeutic chance. In this paper we describe the fascinating
history of Salazopyrin and salicylates from the serendipitous
observations to randomized clinical trials.1. Nanna Svartz and Salazopyrin
Salazopyrin (Sulphasalazine) was synthesized by Nanna
Svartz (1890–1986), professor of Medicine at the Karolinska
Hospital in Stockholm.
Moving from the hypothesis that both rheumatoid arthritis
and ulcerative colitis (UC) were caused by streptococcal
infection (diplostreptococci) and the inflammatory changes
of UC began in the connective tissue of the submucosa, it was
desirable to find a drug capable of concentrating in the
connective tissue. She therefore decided to combine via an
azo-bond Sulphapyridine (SP), a new drug very active on
bacteria, and 5-aminosalicylic acid (5-ASA) active on con-
nective tissue. With the help of a Pharmacia chemist, Philip
Willsted, she was able to produce the compound Salicyl-Figure 1 Chemical structures of Salazopyrin and itsazosulphapyridine named Salazopyrin (SASP)1 (Fig. 1). Svartz
noted that SASP was able to improve not only patients with
rheumatoid arthritis, but also the associated ulcerative
colitis in some patients. The recommended dose was two
500mg tablets 4–6 times daily. At these high doses headache,
nausea, vomiting, fever, cyanosis (methemoglobin), allergic
reactions, jaundice, leucopenia and agranulocytosis were
observed in 15–20% of patients.
Nanna Svartz continued to study SASP during the Second
World War and published her first series of 124 patients in
1948.2 This open study showed that most of the patients (70–
80%) with mild–moderate UC responded well, but relapse
was the rule at drug discontinuation. She suggested that SP
was the active agent.
Bargen of the Mayo Clinic introduced SASP in the Unites
States and published a large series of patients successfully
treated with the new drug.3 In Britain SASP became available
only several years later after 1955 and at the beginning it was
not well accepted by doctors and patients, in particular for
its frequent side effects.
This was an era when the controlled therapeutic trials
were not yet applied to the assessment of drug effectiveness.2. Early controlled trials
The pioneer of the controlled clinical trials (RCTs) in IBD was
Sidney Truelove, who in 1955 published the first RCT on the
effectiveness of corticosteroids in severe UC.4 Sidneycompounds, SP and 5-ASA, linked by an azo-bond.
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gastroenterologists to become involved in clinical trials by
using a biometric approach based on randomization, control
group and blind assessment of the results. He introduced the
first disease activity index in UC (Truelove and Witts index)
that is considered to be a milestone on the road of evidence-
based medicine.4
The first double blind, RCTof Salazopyrin was conducted in
1962 at St Mark's Hospital, London, by Baron et al.5 As it was
postulated that the side effects of SASP were related to
sulphapyridine it was considered the possibility of substituting
sulphadimidine for SP, to reduce side effects. SASP 4 g/day and
salicylsulphadimidine were therefore compared with placebo
in induction of remission in mild cases of UC. SASP but not
sulphadimidine resulted to be superior to placebo. In this study
it was for the first time used as a biometric technique grading
the severity of endoscopic mucosal changes. Side effects were
significantly higher in the SASP group.
Subsequently the same group of St Mark's Hospital showed
for the first time that SASP 2 g/day administered as
maintenance therapy for one year was extremely more
effective than placebo in preventing relapses rate.6 A low
incidence of side effects was observed due to the use of
smaller dose. This was considered a very important clinical
message as it was estimated that 80% of patients who
responded to medical treatment of a first attack of UC, had a
second attack within 12 months.
The efficacy of SASP as maintenance treatment up to
5 years was subsequently confirmed by Dissanayake and
Truelove.7 The prevention of relapse in SASP group was found
to be 12% vs 54% in the placebo group (pb0.001). It was
concluded for the first time that maintenance treatment of
UC with SASP should be continued “indefinitely”, unless
contraindicated by side effects. The importance of these
observations was really relevant from a clinical point of view
as controlled trial had shown that corticosteroids were
totally ineffective in reducing the number of relapses.8,9
SASP became therefore the drug of choice of UC over the
world, but the mechanism of action was still unknown.
An additional side effect was observed, consisting of
reversible, no dose-related oligospermia.10Figure 2 Mechanisms of action of 5-ASA. Mesalazine inhibits
many inflammatory mediators.3. Pharmacokinetics of SASP
In the early seventies studies on the distribution of SASP and
its metabolites showed that most of the SASP reached the
colon intact and here it was split by bacteria azo-reductase
releasing SP and 5-ASA. It was also seen that most of 5-ASA
was eliminated in the faeces.11 The SP was absorbed into
circulation and was thought to be responsible for many of the
adverse events of SASP. These observations were confirmed
by Das who showed that in patients after colectomy the
absorption of SASP was normal, while that of SP was quite
absent.12 Which of these components was the active moiety
was however still unknown.
A great contribution to the history of salicylates came
from Azad Khan and Truelove who provided the elegant
demonstration that 5-ASA was the therapeutic moiety of
SASP. Enemas of SASP, SP and 5-ASA were blindly adminis-
tered to patients with active UC. Improvement was observed
in approximately 30% of the patients receiving SASP or 5-ASA,and in only 5% of those receiving SP.13 The majority of SP is
absorbed from the colon and transported to the liver, where
genetically determined acetylation occurs.14 Slow acetyla-
tors have higher serum level of free SASP and are more prone
to experience adverse effects as they take longer time to
eliminate the drug.15 A substantial percentage of 5-ASA is
absorbed by the colon and metabolized in the epithelium to
inactive acetylated form (N-Ac-5-ASA).
Two important issues were established: 1) SP acts merely
as a carrier which ensures that 5-ASA is released within the
colon and 2) 5-ASA could be given through rectal adminis-
tration. The problem of how to take 5-ASA in the colon by
oral administration without the use of SP was rapidly
resolved by the realization of several delivery systems. At
this point of the history, studies were mainly addressed to the
mechanism of action of 5-ASA.4. Mechanisms of action of 5-ASA
The mechanisms of action of 5-ASA are numerous and not
entirely understood. It has a potent inhibitory effect on a
number of pro-inflammatory mediators released by the
mucosa, including Roms, Leukotrienes, Interleukin 1 and
Tumour Necrosis Factor alpha (TNF α)16–18 (Fig. 2). Recently
it has been shown that the peroxisome proliferator activated
receptor γ (PPARγ) is the major functional receptor mediat-
ing the common salicylate activities in IBD.19 PPAR γ is a
nuclear receptor which plays a central role in the regulation
of inflammatory signalling pathways by inhibiting mucosa
production of inflammatory cytokines. Very recent studies
have demonstrated that 5-ASA is a ligand for PPAR γ and acts
as a PPAR γ agonist.20
The action of 5-ASA is predominantly topical at the site of
inflammation. Studies performed by our group showed that
Figure 4 Rectal mucosal concentration of 5-ASA obtained 1, 2
and 3 days after a 4 g 5-ASA enema. Time 0 represents the mean
mucosal concentration obtained by previous chronic oral
treatment alone. Details in the text.
152 R. Caprilli et al.the anti-inflammatory effect of mesalazine was closely
correlated to its mucosal concentration.21,22 More in
particular, mucosal concentration of 5-ASA was significantly
higher in patients with lower histological inflammation
compared with those with more severe inflammation. A
significant inverse correlation was found between 5-ASA and
sIL-2R mucosal concentrations (Fig. 3). The clinical goal is
therefore to maximize the delivery of 5-ASA to the colonic
affected mucosa. To this purpose, the drug may be either
instilled directly into the rectum and distal colon by
suppositories, enemas or foam or given by mouth with
different systems that assure a colonic drug delivery. In fact,
administered as free 5-ASA, the drug is rapidly absorbed in
the proximal small bowel and is ineffective. To obtain the
best therapeutic results, therefore, it is not important to
increase the oral dose, but assure a topical availability of the
drug onto the inflamed mucosa. In fact it has been
demonstrated that increasing the doses of oral mesalazine
did not result in higher remission rate in UC.23,24
To summarize, oral formulations are better accepted by
the patients but allow adequate mucosal concentration only
in the right colon.25 On the other hand, rectal administration
allows adequate concentration in the rectum and left colon
but is not always well accepted by the patients (leakage,
problem with retention, burning sensation and bloating).5. Rectal 5-ASA administration
Several RCTs have demonstrated that in UC rectally
administered 5-ASA is superior to placebo, rectally adminis-
tered steroids and oral 5-ASA for the induction of sympto-
matic, endoscopic and histological improvement and
remission.26–30
A meta-analysis on 7 trials performed to evaluate
treatments in the management of active distal UC showed
that rectal 5-ASA is significantly superior to rectal corticos-
teroids in inducing remission of symptoms, endoscopy and
histology. The pooled odds ratios (POR) were: 2.42 (95% CI
1.72–3.41), 1.89 (95% CI 1.29–2.76), and 2.03 (95% CI 1.28–
3.20), respectively. The POR vs placebo were 7.71, 6.55, and
6.91 respectively.31Figure 3 Chart showing the inverse correlation between
mucosal concentrations of 5-ASA and sIL-2R. sIL-2R is considered
a marker of mucosal inflammation [adapted from Ref. 22].In addition several RCTs demonstrated the superiority of
rectal 5-ASA compared to oral 5-ASA in the treatment of left-
sided UC,32–34 indicating that the rectal route is the most
effective in this form of UC. Recently, 5-ASA at high dose
continuously given by rectum, was able to modify also the
clinical course of frequently recurrent, severe form of UC.35
Mucosal pharmacokinetics data from our group showed that
after a 4 g enema of 5-ASA given to a patient on oral
treatment alone (day 0), mucosa drug concentration in the
rectal mucosa was significantly higher in day 1 (24 h after
rectal instillation) with respect to day 2 (pb0.0003), day 3
(pb0.000007) and day 0 (pb0.000001). Day 2 did not
differentiate from day 3, but was statistically different
from day 0 (pb0.0001). Day 3 was statistically different from
day 0 (pb0.001) (Fig. 4). These data mean that topical
treatment may give a therapeutic gain even if administered
every three days.6. Oral 5-ASA administration
Due to its topical action rectal 5-ASA is of limited value in UC
proximal to splenic flexure. Thus, many studies were
performed in order to develop new delivery systems able
to release the drug in the colon. Currently 4 types of
formulations are available:1. Compounds that bind 5-ASA to a carrier requiring splitting
of the diazo-bond by bacteria (Olsalazine and Balsalazide);
2. Compounds pH dependent (Asacol);
3. Time-controlled release microsphere (Pentasa);
4. Multi-matrix (MMX) system (Lialda).
The first idea of synthesizing a compound able to deliver
5-ASA to the colon without the side effects of SP came from
Truelove who carried out a new compound called disodium
azodisalycilate (Olsalazine) consisting of two salicylate
radicals linked by an azo-bond.36 The drug was largely
studied by the Oxford group and resulted to be effective in
UC but its use was limited by frequent occurrence of
diarrhoea.37
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a pro-drug consisting of an inert compound 4-Aminobenzoy-
lalanine linked to 5-ASA (Balsalazide).38 This drug after
preliminary encouraging results fell into disuse.
The pH-dependent 5-ASA formulations were introduced
by John Rhodes, from Cardiff, who found a gastro-resistant
acrylic resin, Eudragit-s that dissolves in alkaline medium
and is therefore able to transport into a capsule 5-ASA to the
terminal ileum and caecum where it is delivered (Asacol).39
Another oral 5-ASA preparation consists of 5-ASA coated
with microsphere of ethyl-cellulose that allows slow release
of the medication beginning in the duodenum and extending
into the proximal colon (Pentasa).40
The different mesalazine formulations commercially
available show different profiles of release (Fig. 5). The
limitations of these delivery systems are the frequent daily
dosing together with the number of pills required per day
that reduce patient compliance with long term therapy. In
fact non-adherence to therapy is a widespread problem in
chronic diseases. An estimated 20% to 50% patients with UC
do not take medications as prescribed, resulting in higher
relapse rates with consequent higher health-care costs and,
possibly, greater risk of CRC.
According to ECCO consensus,41 currently most of the
patients with mild–moderate UC are treated by oral
formulations of 5-ASA both for induction and maintenance
of remission. Two Cochrane reviews have been recently
published on the effectiveness of oral 5-ASA for induction
and maintenance of remission in UC. 5-ASA was compared to
placebo or SASP. The conclusions of these reviews were that
oral 5-ASA preparations were superior to placebo and tended
toward therapeutic benefit over SASP for induction of
remission.42 However as far as maintenance therapy, 5-ASA
preparations were superior to placebo, but had a statistically
significant therapeutic inferiority relative to SASP.43
These results are very important from a practice point of
view as oral 5-ASA formulations are the first-line therapy
commonly used for the maintenance of remission in UC. The
consequences of this strategy on health-care costs are
relevant. It has been recently shown that the costs of oral
5-ASA products are the major component of the long term
medicative expenditure in IBD.44 In particular it has been
estimated that the cost of 5-ASA 2.4 g/day is 198 $ monthly,
while that of SASP is 15 $ monthly.45 Considering that SASPFigure 5 Release profiles of various commercially available formul
deliver in the small bowel, whereas Dipentum and SASP in the colonyields comparable or even better benefits of 5-ASA and that
5-ASA is more than 10 folds expensive, the maintenance
treatment with SASP is cost-effective and, if tolerated, could
be recommended.7. New oral mesalazine formulation
Recently a new oral 5-ASA formulation, the MMX system, was
licensed by Giuliani S.p.A., Milan Italy with the purpose of
improving compliance and delivering the 5-ASA throughout
the colon more distally with respect to the previous
formulations.46,47 This formulation contains a double matrix
system that uses a lipophilic matrix dispersed within a
hydrophilic matrix. The tablet core contains microparticles
of 5-ASA in the lipophilic matrix, which are dispersed through
the hydrophilic matrix.
The core is then coated with a pH-dependent, gastro-
resistant polymeric film that is designed to allow the coating
to disintegrate at pH≥7.0. This coating matrix and coating
system is designed to begin dissolution in the terminal ileum.
Here the hydrophilic matrix begins to erode and 5-ASA
diffuses out of the lipophilic matrix. The MMX delivery
system allows the homogeneous distribution of 5-ASA
through the ascending, transverse, descending, sigmoid
colon and rectum.46
Among the oral formulation of 5-ASA Asacol and Pentasa
have been largely investigated by RCTs and represent more
than 90% of the salicylate market. MMXmesalazine, to date is
commercially available only in the US as 1.2 g tablets (Lialda,
Shire, Pharmaceuticals Inc., Wayne, PA). This high dose
formulation should improve compliance. The once-daily MMX
tablet, has been developed with the aim of both increasing
the adherence to oral mesalazine treatment and avoiding the
topical administration of the drug. The efficacy of MMX
mesalazine (1.2 g) was compared with mesalazine enema
(4 g) in patients with left-sided active UC. Clinical remission
occurred in 60% of pts in MMX group and in 50% of enema
group. Similar improvement was seen in the endoscopic and
histological pattern. In addition the adherence rate in
remission was 92% in MMX group and 65% in enema group.47
Recently two RCTs showed that once-daily MMX mesalazine
was efficacious and well tolerated in active mild to moderate
UC for induction of clinical and endoscopic remission.48,49 Noations of oral mesalazine. Pentasa, Claversal and Salofalk mostly
.
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the MMX 2.4 g/day group and MMX 4.8 g/day group.49 Safety
data appear similar to those of other 5-ASA. No serious
adverse events were reported.
Conclusions arising from these studies are that MMX
mesalazine offers effective and convenient 5-ASA therapy
also for distal UC and improves treatment compliance
allowing once- or twice-daily administration.8. New targets of salicylates
Several observational studies have reported the effective-
ness of the long term administration of both SASP and
mesalazine in the prevention of colorectal cancer (CRC) in
UC.50,51 Other studies failed to show chemopreventive effect
of mesalazine.52,53
These studies however are mainly retrospective and
include not very large UC populations. A meta-analysis
including 9 studies allowed to reach a total population of
1.932 UC subjects and showed a protective association
between the use of 5-ASA and CRC (OR=0.51; 95% CI 0.37–
0.69).54
These data are also in keeping with the results of large
epidemiological studies that demonstrated that continue use
of FANS, in particular aspirin, compounds chemically related
to 5-ASA are effective in preventing development of CRC in
the general population. The mechanisms of chemopreven-
tion are not completely understood but the control of
inflammation, a well known trigger in the pathway of colitis–
dysplasia–carcinoma sequence, has been advocated. 5-ASA,
in fact, decreases cell turn-over (by promoting apoptosis
through COX-dependent pathways), acts as antioxidant and
free radical scavenger reducing DNA oxidative stress and
microsatellite instability.55 Recently it has provided evi-
dence supporting the role of activation-induced cytidine
deaminase (AID) as a link between inflammation and UC
associated CRC.56
However, some mechanisms other than control of inflam-
mation should be taken under consideration as the use of
immunosuppressive drugs seems not to reduce cancer risk.57
In fact many observations suggest that 5-ASA can reduce the
risk of cancer by interfering directly with carcinogenetic cell
biology, other than by simply controlling inflammation. Many
other molecular mechanisms have been advocated for the
anti-neoplastic activity of mesalazine.53 Firstly the direct
inhibition of COX-2 by 5-ASA leading to the reduction of many
prostaglandins, including PGE2, that sustains various func-
tions of tumour cells, including proliferation, survival,
angiogenesis and invasion.
Another anti-neoplastic effect of 5-ASA relies on its ability
to inactivate protein phosphatase 2A (PP2A) and the
epidermal growth factor receptor (EGFR) that play key
roles for the development of cancer. Moreover, 5-ASA PPAR-γ
and experimental models demonstrated the direct anti-
neoplastic effects of 5-ASA due to its selective affinity for
PPAR-γ. Recently it has been shown that 5-ASA is a ligand for
PPAR-γ in colonic epithelial cells19,20 and functions as a PPAR-
γ agonist. Moreover NF-kappaB activation has been demon-
strated to be the key to inflammation-associated colon
cancer.58 Mesalazine, therefore, may display its anti-cancer
effect also by blocking the epithelial activation of NF kappa Bitself. This may pave the way to the preventive role of
mesalazine even for sporadic colon cancer. In conclusion a lot
of evidence indicate that 5-ASA interfered with many
inflammatory pathways involved in the initiation and
progress of CRC. In addition, it has also been recently
shown that 5-ASA may directly affect CRC cells interfering
with their growth and survival in particular blocking growth
and promoting apoptosis.51 However it is important to
consider that in vitro studies demonstrated that the anti-
neoplastic effect of 5-ASA is present only with relative high
drug concentrations (10–50 mmol/L), which are not always
reached within the colonic tissue under standard oral
treatment. Therefore, although several molecular mechan-
isms underlie the anti-neoplastic action of mesalazine,
further prospective clinical studies are needed before its
use may be recommended in clinical practice as chemopre-
vention of CRC in UC.9. Conclusive remarks
Seventy years after Nanna Svartz's discovery of SASP,
salicylates still play a central role in the treatment of UC.
The scarce side effects, the relative low cost and the
effectiveness make these drugs still competitive even in the
era of biological agents. The new oral formulations,
improving patient compliance and allowing treatment of
left-sided colitis, may open new roads to an old drug.Conflict of interest
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